Catalent
CTLT
$55.21
Share price
-0.49%
Change (1 day)
25.16%
Change (1 year)
Categories
Catalent is an American pharmaceutical contract research and development company.
Catalent (CTLT) - P/B ratio
P/B ratio as of June 2024 : 2.78
According to Catalent's latest financial reports the company has a price-to-book ratio of 2.78.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Catalent - P/B ratio (from 2014 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 2.20 | 33.49% |
| 2022-12-31 | 1.65 | -67.76% |
| 2021-12-31 | 5.11 | 13.82% |
| 2020-12-31 | 4.49 | 26.62% |
| 2019-12-31 | 3.55 | 22.15% |
| 2018-12-31 | 2.91 | -46.48% |
| 2017-12-31 | 5.43 | -5.1% |
| 2016-12-31 | 5.72 | 11.47% |
| 2015-12-31 | 5.13 | -26.8% |
| 2014-12-31 | 7.01 | |
| 2013-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Supernus Pharmaceuticals
SUPN | 1.54 | -44.70% | 🇺🇸 USA |
 Jazz Pharmaceuticals JAZZ | 1.93 | -30.75% | 🇮🇪 Ireland |
 Intercept Pharmaceuticals
ICPT | 11.1 | 297.80% | 🇺🇸 USA |